```
$%^STN,HighlightOn=  ***,HighlightOff=*** ;


Welcome to STN International!  Enter x x

LOGINID.ssspta1633cxq

PASSWORD
TERMINAL (ENTER 1, 2, 3, OR ?) 2


  ********** Welcome to STN International **********

  NEWS 1       Web Page URLs for STN Seminar Schedule - N. America
  NEWS 2  Apr 08  "Ask CAS" for self-help around the clock
  NEWS 3  Jun 03  New e-mail delivery for search results now available
  NEWS 4  Aug 08  PHARMAMarketLetter(PHARMAML) - new on STN
  NEWS 5  Aug 19  Aquatic Toxicity Information Retrieval (AQUIRE)
                  now available on STN
  NEWS 6  Aug 26  Sequence searching in REGISTRY enhanced
  NEWS 7  Sep 03  JAPIO has been reloaded and enhanced
  NEWS 8  Sep 16  Experimental properties added to the REGISTRY file
  NEWS 9  Sep 16  CA Section Thesaurus available in CAPLUS and CA
  NEWS 10 Oct 01  CASREACT Enriched with Reactions from 1907 to 1985
  NEWS 11 Oct 24  BEILSTEIN adds new search fields
  NEWS 12 Oct 24  Nutraceuticals International (NUTRACEUT) now available on
STN
  NEWS 13 Nov 18  DKILIT has been renamed APOLLIT
  NEWS 14 Nov 25  More calculated properties added to REGISTRY
  NEWS 15 Dec 04  CSA files on STN
  NEWS 16 Dec 17  PCTFULL now covers WP/PCT Applications from 1978 to date
  NEWS 17 Dec 17  TOXCENTER enhanced with additional content
  NEWS 18 Dec 17  Adis Clinical Trials Insight now available on STN
  NEWS 19 Jan 29  Simultaneous left and right truncation added to COMPENDEX,
                  ENERGY, INSPEC
  NEWS 20 Feb 13  CANCERLIT is no longer being updated
  NEWS 21 Feb 24  METADEX enhancements
  NEWS 22 Feb 24  PCTGEN now available on STN
  NEWS 23 Feb 24  TEMA now available on STN
  NEWS 24 Feb 26  NTIS now allows simultaneous left and right truncation
  NEWS 25 Feb 26  PCTFULL now contains images
  NEWS 26 Mar 04  SDI PACKAGE for monthly delivery of multifile SDI results
  NEWS 27 Mar 20  EVENTLINE will be removed from STN
  NEWS 28 Mar 24  PATDPAFULL now available on STN
  NEWS 29 Mar 24  Additional information for trade-named substances without
                  structures available in REGISTRY
  NEWS 30 Apr 11  Display formats in DGENE enhanced
  NEWS 31 Apr 14  MEDLINE Reload
  NEWS 32 Apr 17  Polymer searching in REGISTRY enhanced
  NEWS 33 Apr 21  Indexing from 1947 to 1956 being added to records in
CA/CAPLUS
  NEWS 34 Apr 21  New current-awareness alert (SDI) frequency in
                  WPIDS/WPINDEX/WPIX
  NEWS 35 Apr 28  RDISCLOSURE now available on STN
  NEWS 36 May 05  Pharmacokinetic information and systematic chemical names
                  added to PHAR
  NEWS 37 May 15  MEDLINE file segment of TOXCENTER reloaded
  NEWS 38 May 15  Supporter information for ENCOMPPAT and ENCOMPLIT
updated
  NEWS 39 May 16  CHEMREACT will be removed from STN
  NEWS 40 May 19  Simultaneous left and right truncation added to WSCA
  NEWS 41 May 19  RAPRA enhanced with new search field, simultaneous left and
                  right truncation

  NEWS EXPRESS  April 4 CURRENT WINDOWS VERSION IS V6.01a,
CURRENT
          MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
          AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
  NEWS HOURS    STN Operating Hours Plus Help Desk Availability
  NEWS INTER    General Internet Information
  NEWS LOGIN    Welcome Banner and News Items
  NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
  NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  ********** STN Columbus **********

FILE 'HOME' ENTERED AT 17.13.41 ON 21 MAY 2003

=> FIL BIOSIS EMBASE CAPLUS
COST IN U.S. DOLLARS                 SINCE FILE     TOTAL
                                       ENTRY   SESSION
FULL ESTIMATED COST                     0.21      0.21

FILE 'BIOSIS' ENTERED AT 17.13.54 ON 21 MAY 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC (R)

FILE 'EMBASE' ENTERED AT 17.13.54 ON 21 MAY 2003
COPYRIGHT (C) 2003 Elsevier Science B.V.  All rights reserved

FILE 'CAPLUS' ENTERED AT 17.13.54 ON 21 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s NTTP1 or neuronal tyrosine/threonine phosphatase
MISSING OPERATOR
MISSING OPERATOR
MISSING OPERATOR

=> s NTTP1 or neuronal tyrosine?threonine phosphatase
'?' TRUNCATION SYMBOL NOT VALID WITHIN 'TYROSINE?THREONINE'
'?' TRUNCATION SYMBOL NOT VALID WITHIN 'TYROSINE?THREONINE'
'?' TRUNCATION SYMBOL NOT VALID WITHIN 'TYROSINE?THREONINE'
The truncation symbol '?' may be used only at the end of a search
term.  To specify a variable character within a word use 'I', e.g.,
'womIn' to search for both 'woman' and 'women'.  Enter "HELP
TRUNCATION" at an arrow prompt (=>) for more information

=> s NTTP1 or neuronal tyrosine!threonine phosphatase
L1          2 NTTP1 OR NEURONAL TYROSINE!THREONINE PHOSPHATASE

=> s l1 and (transgen? or knockout or disrupt? or deficien? or delet?)
L2          1 L1 AND (TRANSGEN? OR KNOCKOUT OR DISRUPT? OR
DEFICIEN? OR DELET?
                )

=> d bib abs

L2  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2003 ACS
AN  2002:638352  CAPLUS
DN  137:180791
TI  ***Transgenic*** mice containing neuronal tyrosine/threonine protein
    phosphatase gene ***NTTP1*** ***disruptions*** and their use as
    disease models and for screening for modulators
IN  Allen, Keith D.
PA  USA
SO  U.S. Pat. Appl. Publ., 26 pp.
    CODEN: USXXCO
DT  Patent
LA  English
FAN.CNT 1
    PATENT NO.      KIND  DATE        APPLICATION NO.  DATE
    --------------- ----  ----------  ---------------  --------
PI  US 2002116729   A1    20020822    US 2001-5858     20011204
PRAI US 2000-251802P  P   20001206
AB  The present invention relates to ***transgenic*** animals, as well as
    compns. and methods relating to the characterization of gene function.
    Specifically, the present invention provides ***transgenic*** mice
    comprising a ***disruption*** in the ***NTTP1*** gene encoding a
    neuronal tyrosine/threonine phosphatase, a member of the mitogen-activated
    protein kinase phosphatase gene family which contains a complex
    trinucleotide repeat in the coding region.  To investigate the role of
    ***NTTP1*** , ***disruptions*** in the ***NTTP1*** genes are
    produced by homologous recombination using 5' and 3' arms in a targeting
    construct.  ***Transgenic*** mice contg. ***NTTP1***
    ***disruptions*** exhibit anti-depressive behavior, relative to
    wild type mice, as shown by a decrease in immobile time when tail
    suspended.  Such ***transgenic*** mice are useful as models for
    disease and for identifying agents that modulate gene expression and gene
    function, and as potential treatments for various disease states and
    disease conditions.


=> d bib abs l1

L1  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2003 ACS
AN  2002:638352  CAPLUS
DN  137:180791
TI  Transgenic mice containing neuronal tyrosine/threonine protein phosphatase
    gene ***NTTP1*** disruptions and their use as disease models and for
    screening for modulators
IN  Allen, Keith D.
PA  USA
SO  U.S. Pat. Appl. Publ., 26 pp.
    CODEN: USXXCO
DT  Patent
LA  English
FAN.CNT 1
    PATENT NO.      KIND  DATE        APPLICATION NO.  DATE
    --------------- ----  ----------  ---------------  --------
PI  US 2002116729   A1    20020822    US 2001-5858     20011204
PRAI US 2000-251802P  P   20001206
AB  The present invention relates to transgenic animals, as well as compns.
    and methods relating to the characterization of gene function.
    Specifically, the present invention provides transgenic mice comprising a
    disruption in the ***NTTP1*** gene encoding a neuronal
```

tyrosine/threonine phosphatase, a member of the mitogen-activated protein kinase phosphatase gene family which contains a complex trinucleotide repeat in the coding region. To investigate the role of ***NTTP1*** , disruptions in the ***NTTP1*** genes are produced by homologous recombination using 5' and 3' arms in a targeting construct. Transgenic mice contg ***NTTP1*** disruptions exhibit anti-depressive behavior, relative to wild-type mice, as shown by a decrease in immobile time when tail suspended. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.

=> d bib abs l1 1-
YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N) y

L1 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS
AN 2002:638352 CAPLUS
DN 137:180791
TI Transgenic mice containing neuronal tyrosine/threonine protein phosphatase gene ***NTTP1*** disruptions and their use as disease models and for screening for modulators
IN Allen, Keith D
PA USA
SO U.S. Pat. Appl. Publ., 26 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002116729	A1	20020822	US 2001-5858	20011204
PRAI US 2000-251802P	P	20001206		

AB The present invention relates to transgenic animals, as well as compns and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising a disruption in the ***NTTP1*** gene encoding a neuronal tyrosine/threonine phosphatase, a member of the mitogen-activated protein kinase phosphatase gene family which contains a complex trinucleotide repeat in the coding region. To investigate the role of ***NTTP1*** , disruptions in the ***NTTP1*** genes are produced by homologous recombination using 5' and 3' arms in a targeting construct. Transgenic mice contg ***NTTP1*** disruptions exhibit anti-depressive behavior, relative to wild-type mice, as shown by a decrease in immobile time when tail suspended. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.

L1 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS
AN 2001:447761 CAPLUS
DN 135:180233
TI The in vivo neuromodulatory effects of the herbal medicine Ginkgo biloba
AU Watanabe, Coran M. H.; Wolffram, Siegfried; Ader, Peter; Rimbach, Gerald; Packer, Lester; Maguire, John J.; Schultz, Peter G.; Gohil, Kishorchandra
CS Department of Chemistry, Scripps Research Institute, La Jolla, CA, 92037, USA
SO Proceedings of the National Academy of Sciences of the United States of America (2001), 98(12), 6577-6580
CODEN: PNASA6; ISSN: 0027-8424
PB National Academy of Sciences
DT Journal
LA English
AB Exts. of G. biloba leaves are consumed as dietary supplements to counteract chronic age-related neurol. disorders. High-d. oligonucleotide microarrays were used to define the transcriptional effects in the brain cortex and hippocampus of adult female C57BL6 mice fed diets supplemented with the herbal ext. Gene expression RT-PCR anal. was then focused on the mRNAs that showed >3-fold change in their expression. In the brain cortex, mRNAs for neuronal tyrosine/threonine phosphatase 1 and microtubule-associd. protein factor tau were enhanced. Hyperphosphorylated tau is the major constituent of the neurofibrillary tangles in the brain of Alzheimer disease patients. The expression of alpha -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid channels (AMPA-2 receptor), calcium and chloride channels, prolactin, and growth hormone (GH), all of which are associd. with brain function, were also up-regulated. In the hippocampus, only transthyretin mRNA was upregulated. Transthyretin has a role in hormone transport in the brain and possibly a neuroprotective role by amyloid-.beta. sequestration. Thus, diets supplemented with G. biloba leaf ext. have notable neuromodulatory effects in vivo. The data illustrate the utility of genome-wide expression monitoring to investigate the biol. actions of complex herbal exts.
RE CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	SESSION	TOTAL
FULL ESTIMATED COST		30.41	30.62

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	SESSION	TOTAL
CA SUBSCRIBER PRICE		-2.60	-2.60

STN INTERNATIONAL LOGOFF AT 17:17:43 ON 21 MAY 2003